Compared with oral glucocorticosteroids, the systemic side effects are relatively mild and the local effects are stronger, which can reduce or lower the dosage of oral glucocorticosteroids, and it is clinically used to control bronchial asthma. For the acute exacerbation of bronchial asthma, co-corticosterone cannot be used as a relieving drug, and it should be combined with inhaled short-acting β2 agonist, which has good efficacy in controlling bronchial asthma. Long-term use of co-codone may cause a series of side effects, mainly including immunosuppression and local lesions in the mouth, with hoarseness, oral fungal infections, and ulcer formation. In children, long-term use may lead to suppression of the adrenocortical axis and developmental delay in children. There may also be a decrease in the patient’s immune function and the development of systemic infections.